Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2067-2070

  Brun Pascaud, Monique ^a   Chau, Françoise ^a   Garry, Louis ^a   Jacobus, David ^d   Derouin, Francis ^b   Girard, Pierre Marie ^a,c  

^a BICHAT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL ROTHSCHILD   (France)

^d Jacobus Pharmaceutical Co Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; DIHYDROFOLATE REDUCTASE; EPIROPRIM; N [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] N' ISOPROPYLIMIDOCARBONIMIDIC DIAMIDE; PYRIMETHAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORTICOSTEROID THERAPY; DOSE RESPONSE; ENZYME INHIBITION; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE TEST; INFECTION RISK; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0029818730     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2067     Document Type: Article

References (28)

1. Bozzette, S. A., D. M. Finkelstein, S. A. Spector, P. Frame, W. G. Powderly, H. Weili, L. Philips, D. Craven, C. Van der Horst, J. Feinberg, and The NIAID AIDS Clinical Trials Group. 1995. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. Am. J. Med. 332:693-699.
2. 1a. Brun-Pascaud, M., F. Chau, F. Derouin, and P. M. Girant. 1995. Experimental evaluation of epiroprim alone or combined with dapsone in dual pneumocystosis and toxoplasmosis infection in a rat model, abstr. B53, p. 35. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Brun-Pascaud, M., F. Chau, A. M. Simonpoli, P. M. Girant, F. Derouin, and J. J. Pocidalo. 1994. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. J. Infect. Dis. 170:653-658.
4. Brun-Pascaud, M., P. M. Girant, F. Chau, F. Derouin, J. J. Pocidalo, and D. Jacobus. 1995. Experimental evaluation of PS-15 (a biguanide folate antagonist) alone or combined with dapsone in dual pneumocystosis and toxoplasmosis infection in a rat model, abstr. 301, p. 110. In Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections. American Society for Microbiology, Washington, D.C.
5. Canfield, C. J., W. K. Milhous, A. L. Ager, R. N. Rossan, T. R. Sweeney, N. J. Lewis, and D. P. Jacobus. 1993. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. J. Trop. Med. Hyg. 49:121-126.
6. Carr, A., A. S. Gross, J. M. Hoskins, R. Penny, and D. A. Cooper. 1994. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 8:333-337.
7. Carr, A., B. Tindall, R. Penny, and D. A. Cooper. 1992. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 6:165-171.
8. Chang, H. R., D. Arsenijevic, R. Comte, A. M. Polak, R. L. Then, and J. C. Pechère. 1994. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob. Agents Chemother. 38:1803-1807.
9. Comley, J. C. W. 1995. In vitro susceptibility of Pneumocystis carinii to antimicrobial agents and specific inhibitors. In Proceedings of the 1st Specialized Meeting In Vitro Systems in Pneumocystis Research of the European Concerted Action, biomed 1: Pneumocystis and pneumocystosis.
10. Comley, J. C. W., and A. M. Sterling. 1995. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J. Eukaryot. Microbiol. 41:540-546.
11. Derouin, F., C. Piketty, C. Chastang, F. Chau, B. Rouveix, and J. J. Pocidalo. 1991. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob. Agents Chemother. 35:252-255.
12. Girant, P. M., R. Landman, C. Gaudebout, et al. 1993. A controlled trial of dapsone-pyrimethamine versus pentamidine aerosols for primary prophylaxis of Pneumocystis carinii pneumonia and opportunistic toxoplasmosis inpatients with human immunodeficiency virus infection. N. Engl. J. Med. 328:1514-1520.
13. Gosey, L. L., R. M. Howard, F. G. Wilebsky, F. P. Ognibene, T. C. Wu, V. J. Gill, and J. D. MacLowry. 1985. Advantages of a modified toluidine blue O stain and bronchoalveolar lavage for the diagnosis of Pneumocystis carinii pneumoniae. J. Clin. Microbiol. 22:803-807.
14. Hardy, W. D., J. Feinberg, D. M. Finkelstein, M. E. Power, W. He, C. Kaczka, P. T. Frame, M. Holmes, H. Waskin, R. J. Fass, W. G. Powderly, R. T. Steigbigel, A. Zuger, R. S. Holzman, and The Aids Clinical Trials Groups. 1992. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 02. N. Engl. J. Med. 327:1842-1848.
15. Hartman, P., and R. L. Then. 1993. Folic acid biosynthesis inhibitors as agents against multiple opportunistic pathogens: the potential of epiroprim, abstr. 382, p. 189. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Hoover, D. R., A. J. Saah, A. J. Bacellar, J. Phair, R. Detels, R. Anderson, and R. A. Kaslow for the Multicenter AIDS Cohort Study. 1993. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N. Engl. J. Med. 329:1922-1926.
17. Hughes, W. T., D. P. Jacobus, C. Canfield, and J. Killmar. 1993. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist. Antimicrob. Agents Chemother. 37:1417-1419.
18. Hughes, W. T., J. T. Killmar, and H. S. Oz. 1994. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in animal model. J. Infect. Dis. 170:906-911.
19. Jorde, U. P., H. W. Horowitz, and G. P. Wormser. 1993. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole intolerant HIV-infected individuals. AIDS 7:355-359.
20. Kovacs, J. A., C. J. Allegra, J. Beaver, D. Boarman, M. Lewis, J. E. Parrillo, B. Chabner, and H. Masur. 1989. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J. Infect. Dis. 160:312-320.
21. Martinez, A., C. J. Allegra, and J. A. Kovacs. 1996. Efficacy of epiroprim (Roll-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Am. J. Trop. Med. Hyg. 54:249-252.
22. Mehlborn, H., W. Dankert, P. G. Hartman, and R. L. Then. 1995. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. Parasitol. Res. 81:296-301.
23. Meyer, S. C. C., S. K. Majumder, and M. H. Cynamon. 1995. In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex. Antimicrob. Agents Chemother. 39:1862-1863.
24. Piketty, C., F. Derouin, B. Rouveix, and J.-J. Pocidalo. 1990. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in blood, lungs, and brain of infected mice. Antimicrob. Agents Chemother. 34:1467-1472.
25. Schneider, M. M. E., A. I. M. Hoepelman, J. K. M. Eeftinck Schattenkerk, T. L. Nielsen, Y. Van Der Graaf, J. P. H. J. Frissen, I. M. E. Van Der Ende, A. F. P. Kolsters, J. C. C. Borleffs, and The Dutch AIDS Treatment Group. 1992. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N. Engl. J. Med. 327:1836-1841.
26. Then, R. L., E. Böhni, P. Angehrn, H. Plozza-Nottebrock, and K. Stoeckel. 1982. New analogs of trimethoprim. Rev. Infect. Dis. 4:372-377.
27. United States Public Health Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection. 1992. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Morbid. Mortal. Weekly Rep. 41:1-11.
28. Walzer, P. D., J. Foy, P. Steele, and M. White. 1993. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob. Agents Chemother. 37:1436-1443.